Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab

Solera, Javier T; Arbol, Berta G; Ferreira, Victor H; Kurtesi, Alexandra; Hu, Queenie; Ierullo, Matthew; Valverde-Zuniga, Adriana; Raslan, Ismail R.; Nasir, Asma; Grizales, Clara; Hardy, W. Rod; Kulasingam, Vathany; Gingras, Anne‐Claude; Humar, Atul; Kumar, Deepali

doi:10.1016/s1473-3099(23)00208-6

Cited by 14 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an alternative prophylaxis strategy, French researchers have reported the efficacy of tixagevimab/cilgavimab in reducing the morbidity and severity of SARS-CoV-2 in KTXRs who failed to develop a protective humoral response after at least three doses of an mRNA vaccine administration during the Omicron BA.1-BA.2 epidemic 52 , 53 . Recent clinical studies suggested that tixagevimab/cilgavimab improved the neutralization of BA.4/5, but this effect was not observed against BQ.1.1 and XBB.1.5 54 , 55 . Therefore, the effect of monoclonal antibody as prophylaxis for COVID-19 infection may be limited.…”

Section: Discussionmentioning

confidence: 99%

Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients

Kawashiro,

Suzuki,

Nogimori

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Although the mRNA SARS-CoV-2 vaccine has improved the mortality rate in the general population, its efficacy against rapidly mutating virus strains, especially in kidney transplant recipients, remains unclear. We examined the anti-SARS-CoV-2 spike protein IgG antibody and neutralizing antibody titers and cellular immunity against B.1.1, BA.1, and BA.5 antigens in 73 uninfected kidney recipients and 16 uninfected healthy controls who received three doses of an mRNA SARS-CoV-2 vaccine. The IgG antibody titers were significantly lower in recipients than in healthy controls. Similarly, neutralizing antibody titers against three viral variants were significantly lower in recipients. When the virus was mutated, the neutralizing antibody titers decreased significantly in both groups. In cellular immunity analysis, the number of spike-specific CD8 + non-naïve T cells against three variants significantly decreased in recipients. Conversely, the frequency of spike-specific Th2 CD4 + T-cells in recipients was higher than that in healthy controls. Nineteen recipients and six healthy controls also received a bivalent omicron-containing booster vaccine, leading to increase IgG and neutralizing antibody titers in both groups. After that, eleven recipients and five healthy controls received XBB.1.5 monovalent vaccines, increasing the neutralizing antibody titers against not only XBB.1.5, but also EG.5.1 and BA.2.86 antigens in kidney recipients. Although kidney recipients did not gain sufficient immunity against Omicron BA.5 with the third dose of vaccine, humoral response against mutant SARS-CoV-2 lineages significantly increased after bivalent Omicron-containing booster vaccine and the XBB.1.5 monovalent vaccine. Therefore, it is important for kidney recipients to continue to administer updated vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients

Kawashiro,

Suzuki,

Nogimori

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Although our study was not designed to test statistical significance, most cases included in our report who received T-C did not have COVID-19 within 6 months of administration. Furthermore, while seven patients had COVID-19 post-T-C, only one patient (14%) developed severe COVID-19, and this occurred during a period when BA.5 was the most prevalent variant of concern circulating in the US and several reports showed decrease activity of this monoclonal antibody (34,43,44), eventually leading to the US FDA to revoke the EUA (26). In addition, the episode of severe disease occurred 139 after the first dose, close to the 180 days recommendation for re-dosing.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study

et al. 2023

View full text Add to dashboard Cite

From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28–135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.

show abstract

Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023

Solera,

Árbol,

Mittal

et al. 2024

American Journal of Transplantation

View full text Add to dashboard Cite

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab

Cited by 14 publications

References 6 publications

Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients

Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients

SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study

Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023

Contact Info

Product

Resources

About